**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:

Date: August 3, 2005 Name: C. Noel Kaman, Reg. No. 51,857 Signature: C. Noel Kaman

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Appln. of: **Goddard et al.**

Appln. No.: **10/735,014**

Filed: **December 12, 2003**

For: **SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME**

Examiner: **Sumesh Kaushal**

Art Unit: **1636**

Attorney Docket No: **10466/486 P2548P1C13-C1**

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(c), Applicants hereby cite the following reference(s):

OTHER ART
Coico, R (Ed.), AM et al. Proliferative Assays For T Cell Function. Current Protocols in Immunology, 1991 Vol. 1; 3.12.1-3.12.14.
Steinman, RM. The Dendritic Cell Advantage: New Focus For Immune-Based Therapies. Drug News Perspect Dec. 2000; 13(10); 581-586.
Gubler, U et al. Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor. Proc. Natl. Acad. Sci. USA, May 1991; Vol. 88; 4143-4147.
Peterson, AC et al. Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma. Journal of Clinical Oncology, June 2003; Vol. 21(12); 2342-2348.
Thurner, B, et al. Vaccination With Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma. J. Exp. Med. Dec. 1999; Vol. 190(11); 1669-1678.

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of

the listed references is in English, no further commentary is believed to be necessary, 37 C.F.R. §1.98(a)(3). Applicants respectfully request the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.


By submitting this Statement, Applicants are attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Pursuant to 37 C.F.R. §1.97(c), Applicants include herewith this submission a processing fee in the amount of \$180.00 pursuant to 37 C.F.R. §1.17(p). Applicants have enclosed a check covering this fee, or authorized charging the fee to a deposit account or credit card, as indicated in the Transmittal accompanying this Statement.

Respectfully submitted,

3 Aug 2005  
Date

C. Noel Kaman  
C. Noel Kaman (Reg. No.51,857)



FORM PTO-1449	SERIAL NO. 10/735,014	CASE NO. 10466/486 P2548P1C13-C1
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE December 12, 2003	GROUP ART UNIT 1636
APPLICANT(S): Goddard, et al.		

#### REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
---------------------	--	------	------	--------------------	----------------

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
---------------------	--	------	---------	--------------------	--------------------------

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS <small>(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.</small>	
	A1	Coico, R (Ed.), AM et al. Proliferative Assays For T Cell Function. Current Protocols in Immunology, 1991 Vol. 1; 3.12.1-3.12.14.
	A2	Steinman, RM. The Dendritic Cell Advantage: New Focus For Immune-Based Therapies. Drug News Perspect Dec. 2000; 13(10); 581-586.
	A3	Gubler, U et al. Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor. Proc. Natl. Acad. Sci. USA, May 1991; Vol. 88; 4143-4147.
	A4	Peterson, AC et al. Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma. Journal of Clinical Oncology, June 2003; Vol. 21(12); 2342-2348.
	A5	Thurner, B, et al. Vaccination With Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma. J. Exp. Med. Dec. 1999; Vol. 190(11); 1669-1678.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.